X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
r-chop (794) 794
index medicus (622) 622
humans (568) 568
oncology (452) 452
rituximab (408) 408
male (400) 400
female (390) 390
aged (380) 380
middle aged (380) 380
hematology (368) 368
chemotherapy (331) 331
prognosis (315) 315
lymphoma, large b-cell, diffuse - drug therapy (299) 299
lymphomas (298) 298
non-hodgkins-lymphoma (295) 295
adult (288) 288
antineoplastic combined chemotherapy protocols - therapeutic use (281) 281
elderly-patients (269) 269
diffuse large b-cell lymphoma (252) 252
aged, 80 and over (239) 239
survival (222) 222
cancer (220) 220
treatment outcome (190) 190
lymphoma, large b-cell, diffuse - mortality (182) 182
lymphoma, large b-cell, diffuse - pathology (164) 164
b-cell lymphoma (161) 161
doxorubicin - administration & dosage (160) 160
cyclophosphamide - administration & dosage (156) 156
young adult (156) 156
vincristine - administration & dosage (154) 154
lymphoma (153) 153
retrospective studies (143) 143
prednisone - administration & dosage (138) 138
antineoplastic combined chemotherapy protocols - administration & dosage (131) 131
cyclophosphamide (128) 128
disease-free survival (125) 125
care and treatment (124) 124
dlbcl (124) 124
adolescent (119) 119
cyclophosphamide - therapeutic use (119) 119
vincristine - therapeutic use (118) 118
doxorubicin - therapeutic use (117) 117
prednisone - therapeutic use (114) 114
lymphoma, large b-cell, diffuse - diagnosis (113) 113
antibodies, monoclonal, murine-derived - administration & dosage (109) 109
chemotherapy plus rituximab (109) 109
lymphoma, large b-cell, diffuse - genetics (108) 108
analysis (106) 106
antibodies, monoclonal, murine-derived - therapeutic use (104) 104
hemic and lymphatic diseases (103) 103
immunohistochemistry (96) 96
neoplasm staging (93) 93
medicine & public health (90) 90
vincristine (86) 86
expression (85) 85
follicular lymphoma (85) 85
antibodies, monoclonal, murine-derived (84) 84
survival analysis (84) 84
doxorubicin (79) 79
kaplan-meier estimate (77) 77
trial (74) 74
diffuse large b cell lymphoma (73) 73
lymphoma, large b-cell, diffuse - metabolism (73) 73
therapy (73) 73
classification (72) 72
follow-up studies (72) 72
survival rate (70) 70
antineoplastic combined chemotherapy protocols - adverse effects (69) 69
risk factors (67) 67
immune system diseases (66) 66
lymphocytes b (64) 64
gene-expression (62) 62
non-hodgkin-lymphoma (62) 62
anthracyclines (61) 61
randomized controlled-trial (61) 61
lymphoma, large b-cell, diffuse - therapy (60) 60
phase-ii (60) 60
prednisone (60) 60
chop (58) 58
gene expression (58) 58
prognostic-significance (58) 58
research (57) 57
multivariate analysis (54) 54
patients (54) 54
doxorubicin - adverse effects (53) 53
corticosteroids (52) 52
cyclophosphamide - adverse effects (52) 52
vincristine - adverse effects (52) 52
abridged index medicus (51) 51
antineoplastic agents (51) 51
antimitotic agents (50) 50
antineoplastic agents - therapeutic use (50) 50
health aspects (50) 50
chop chemotherapy (49) 49
non-hodgkin's lymphomas (49) 49
protein expression (49) 49
medical prognosis (48) 48
plus rituximab (48) 48
transplantation (48) 48
diagnosis (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (846) 846
Japanese (17) 17
German (7) 7
French (4) 4
Russian (4) 4
Hungarian (2) 2
Korean (2) 2
Serbian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British journal of haematology, ISSN 0007-1048, 9/2015, Volume 170, Issue 5, pp. 679 - 686
Patients with early stage diffuse large B-cell lymphoma (DLBCL) receive RCHOP alone or with involved field radiotherapy (IFRT). Anti-CD20 radioimmunotherapy... 
R-CHOP | large cell lymphoma | radioimmunotherapy
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma... 
DLBCL | comorbidities | R-CHOP | elderly | dose-attenuation
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 28, pp. 3452 - 3459
Journal Article
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 04/2017, Volume 13, Issue 10, pp. 859 - 862
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 707 - 714
Abstract Background Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) ≥3 are at higher risk for relapse after a... 
Everolimus | Large cell lymphoma | Adjuvant therapy | MULTICENTER | PLACEBO | CYCLOPHOSPHAMIDE | R-CHOP | DOXORUBICIN | MAINTENANCE RITUXIMAB | everolimus | OLDER PATIENTS | ONCOLOGY | VINCRISTINE | ELDERLY-PATIENTS | large cell lymphoma | REMISSION | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 12/2014, Volume 28, Issue 12, pp. 2367 - 2375
Journal Article
Infectious Diseases in Clinical Practice, ISSN 1056-9103, 11/2018, Volume 26, Issue 6, pp. e85 - e87
ABSTRACTWest Nile virus (WNV) is a mosquito-borne infectious disease that can produce potentially life-threatening meningoencephalitis in immunocompromised... 
immunosuppression | meningoencephalitis | immunocompromised | R-CHOP | West Nile virus
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2018, Volume 29, Issue 12, pp. 2363 - 2370
Abstract Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma... 
Cell-of-origin | Deconvolution | DLBCL | Digital expression analysis | Microenvironment | Prognosticators | SIGNATURES | R-CHOP | TUMOR | CHEMOTHERAPY | microenvironment | deconvolution | B-CELL LYMPHOMA | ONCOLOGY | digital expression analysis | DEREGULATION | STROMA | cell-of-origin | prognosticators | Original
Journal Article
Leukemia and Lymphoma, ISSN 1042-8194, 01/2019, Volume 60, Issue 1, pp. 172 - 179
The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab,... 
VR-CAP | dose intensity | bortezomib | R-CHOP | LYM-3002 | Mantle cell lymphoma | MULTIPLE-MYELOMA | GUIDELINES | CHEMOTHERAPY | THERAPY | ONCOLOGY | RITUXIMAB | HEMATOLOGY
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 20, pp. 4021 - 4031
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like... 
MOLECULAR SUBTYPES | PLUS CYCLOPHOSPHAMIDE | PROGNOSTIC IMPACT | R-CHOP | POOR-PROGNOSIS | T(14/18) | DISTINCT | PREDICTS SURVIVAL | HEMATOLOGY | NF-KAPPA-B | BCL-2 EXPRESSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | B-Lymphocyte Subsets - classification | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Transcriptome | Male | Proto-Oncogene Proteins c-bcl-2 - metabolism | Lymphocyte Activation - genetics | Aged, 80 and over | Vincristine - administration & dosage | Adult | B-Lymphocyte Subsets - immunology | Female | Retrospective Studies | Gene Expression Regulation, Neoplastic - physiology | Doxorubicin - administration & dosage | B-Lymphocyte Subsets - physiology | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Risk Factors | Rituximab | International Cooperation | Proto-Oncogene Proteins c-myc - metabolism | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | B-Lymphocyte Subsets - metabolism | Survival Analysis | Aged | Proto-Oncogene Proteins c-myc - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Cohort Studies | Index Medicus | Abridged Index Medicus | Plenary Paper | CME
Journal Article